Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event...

Area of Science:

• Pharmacovigilance
• Hematology
• Oncology

Background:

• Novel medications have transformed multiple myeloma (MM) treatment.
• These advancements are associated with various adverse events (AEs).
• Understanding the safety profiles of new MM drugs is crucial.

Purpose of the Study:

• To comprehensively overview adverse events (AEs) for four new MM medications: daratumumab, ixazomib, elotuzumab, and panobinostat.
• To analyze trends and patterns in reported AEs and deaths.
• To inform clinical practice and future research directions.

Main Methods:

• Descriptive retrospective analysis of the FDA Adverse Event Reporting System (FAERS) database.
• Data collected from 2015 to 2022.
• Inclusion of medication names, patient demographics, AE details, and reporter types.

Main Results:

• Over 367,000 AEs were reported for novel MM drugs between 2015-2022.
• Ixazomib showed the highest number of AEs (206,243) and deaths (24,206).
• AEs were most frequent in patients aged 55-74 years, with a significant increase in ixazomib reports.

Conclusions:

• Ixazomib is associated with the highest reported AEs and deaths among the studied novel MM medications.
• Clinicians must be aware of ixazomib's AE profile.
• Further investigation is required to understand and mitigate these safety concerns, with a focus on younger patients.